US2007172452A1PendingUtilityA1

Methods for treating viral infection using il-28 and il-29

64
Assignee: ZYMOGENETICS INCPriority: Oct 23, 2002Filed: Oct 11, 2006Published: Jul 26, 2007
Est. expiryOct 23, 2022(expired)· nominal 20-yr term from priority
A61P 31/20A61P 7/00A61P 31/14A61P 31/12A61K 38/20A61K 47/60A61K 38/21A61P 1/16C07K 14/54Y02A50/30
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

Claims

exact text as granted — not AI-modified
1 . A method of treating a viral infection comprising administering to an immunocompromised mammal with a hepatitis infection a therapeutically effective amount of a polypeptide comprising amino acid residues 1-175 of SEQ ID NO:28, wherein after administration of the polypeptide the hepatitis infection is reduced.  
     
     
         2 . The method of  claim 1  wherein the polypeptide is conjugated to a polyalkyl oxide moiety.  
     
     
         3 . The method of  claim 2  wherein the polyalkyl oxide moiety is a polyethylene glycol.  
     
     
         4 . The method of  claim 1  wherein the hepatitis infection is a hepatitis B infection.  
     
     
         5 . The method of  claim 1  wherein the hepatitis infection is a hepatitis C infection.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.